Product Images Mannitol

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 3 images provide visual information about the product associated with Mannitol NDC 0990-7715 by Icu Medical Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - mannitol 01

Chemical Structure - mannitol 01

PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - mannitol 02

PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - mannitol 02

This is a description of a 250 mL container of 20% Mannitol Injection, USP, manufactured by 1CU Medical Inc., containing 50 g/250 mL (200 mg/mL) of mannitol. Each 100 mL of the injection contains 20 grams of mannitol and may contain sodium bicarbonate for pH adjustment. The solution is sterile and nonpyrogenic, and is for intravenous use only. Additives may be incompatible, so users should consult with a pharmacist, if available, and mix the additives thoroughly and aseptically. The solution should be administered intravenously within a specific range of temperature and should be discarded if unused. If the solution is not clear, the container is damaged or crystals form, the solution should not be used. The container is a single-dose container and must not be used in series connections. The text contains a warning about contraindication in severe renal impairment.*

PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - mannitol 03

PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - mannitol 03

This is a description of 20% Mannitol Injection, USP contained in a single-dose container of 500mL for intravenous use. It contains Mannitol at a concentration of 200mg/mL with sodium bicarbonate for pH adjustment. Each 100mL contains 20 grams of Mannitol. The solution is sterile, non-pyrogenic, and has a calculated osmolality of 1098 mOsmol/L. It is indicated for use with careful inspection and must not be used in series connections. If crystals form, the solution should be agitated to dissolve and administered intravenously at 30 to 37 °C (86 to 986 °F). The solution may have incompatibilities with additives, and it is recommended to consult with a pharmacist when introducing additives to the solution. The dosage information can be found in the insert, and this solution is contraindicated in severe renal impairment.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.